Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease ...

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Intellia expects to present additional data from the ongoing Phase 1/2 study in the second half of 2025. The Company is on track to submit a Biologics License Application (BLA) in the second half of ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its ...

AstraZeneca, which last week announced a $50bn plan for US development, declined to comment. Pfizer, Abbvie, and Germany’s ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.